Back to Authors

Blankenbiller, Tricia

0009-0009-9973-4744

A5041587271 | I4210139373

Mayo Clinic

Teva Pharmaceuticals (United States)

Citations 4

Efficacy of Two Dose Regimens of Subcutaneous Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine (S32.005)

Neurology | December 7, 2023 | Volume: 90 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.90.15_supplement.s32.005

Efficacy Of Fremanezumab in Patients With Chronic Migraine With or Without Concomitant Use of Preventive Medication (P4.099)

Neurology | December 7, 2023 | Volume: 90 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.90.15_supplement.p4.099

Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine (P4.093)

Neurology | December 7, 2023 | Volume: 90 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.90.15_supplement.p4.093

Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine

JAMA | May 17, 2018 | Volume: 319 | Issue: 19 | Pages: 1999

10.1001/jama.2018.4853 | PMID 29800211